Evidence map›Paper›PMID 31515456›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2019

Transcriptomic Heterogeneity of Androgen Receptor Activity Defines a

Daniel E Spratt, Mohammed Alshalalfa, Nick Fishbane, Adam B Weiner, Rohit Mehra, Brandon A Mahal, Jonathan Lehrer, Yang Liu, Shuang G Zhao, Corey Speers and 13 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 82 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
82citing papers in PubMed, 2 pooled it
9.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

82 citing papers in PubMed, 2 syntheses or guidelines pooled it, 127 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Transcriptional profiling identifies an androgen receptor activity-low, stemness program associated with enzalutamide resistance.Proceedings of the National Academy of Sciences of the United States of America · 2020
    Trial
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article

22 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

23 authors at 12 institutions in 2 countries.

Daniel E Spratt *Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan. sprattda@med.umich.edu e-shaeffer@northwestern.edu arul@med.umich.edu.
Mohammed Alshalalfa *Department of Radiation Oncology, University of California, San Francisco, San Francisco, California.
Nick FishbaneDecipher Biosciences, San Diego, California.
Adam B WeinerDepartment of Urology, Feinberg School of Medicine, Northwestern University, Illinois.
Rohit MehraDepartment of Pathology, University of Michigan, Ann Arbor, Michigan.
Brandon A MahalDepartment of Radiation Oncology, Dana-Farber/Brigham and Women's Cancer Center and Harvard Medical School, Boston, Massachusetts.
Jonathan LehrerDecipher Biosciences, San Diego, California.
Yang LiuDecipher Biosciences, San Diego, California.
Shuang G ZhaoDepartment of Radiation Oncology, University of Michigan, Ann Arbor, Michigan.
Corey SpeersDepartment of Radiation Oncology, University of Michigan, Ann Arbor, Michigan.ORCID 0000-0002-2362-2860
Todd M MorganDepartment of Urology, Michigan Medicine, Ann Arbor, Michigan.
Adam P DickerDepartment of Radiation Oncology, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania.
Stephen J FreedlandDepartment of Surgery, Division of Urology, Cedars-Sinai Medical Center, Los Angeles, California.
R Jeffery KarnesDepartment of Urology, Mayo Clinic, Rochester, Minnesota.
Sheila WeinmannCenter for Health Research, Kaiser Permanente Northwest, Portland, Oregon.
Elai DavicioniDecipher Biosciences, San Diego, California.ORCID 0000-0001-9136-099X
Ashley E RossTexas Urology Specialists, Dallas, Texas.
Robert B DenDepartment of Radiation Oncology, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania.ORCID 0000-0002-8653-1763
Paul L NguyenDepartment of Radiation Oncology, Dana-Farber/Brigham and Women's Cancer Center and Harvard Medical School, Boston, Massachusetts.
Felix Y FengDepartment of Radiation Oncology, University of California, San Francisco, San Francisco, California.
Tamara L LotanDepartment of Pathology, Department of Oncology, Johns Hopkins School of Medicine, Baltimore, Maryland.
Arul M ChinnaiyanDepartment of Pathology, University of Michigan, Ann Arbor, Michigan. sprattda@med.umich.edu e-shaeffer@northwestern.edu arul@med.umich.edu.
Edward M SchaefferDepartment of Urology, Feinberg School of Medicine, Northwestern University, Illinois. sprattda@med.umich.edu e-shaeffer@northwestern.edu arul@med.umich.edu.
University of Michigan · USDecipher Biosciences (Canada) · CADana-Farber Brigham Cancer Center · USNorthwestern University · USThomas Jefferson University · USUniversity of California, San Francisco · USCedars-Sinai Medical Center · USJohns Hopkins University · USKaiser Permanente Center for Health Research · USMayo Clinic · USMichigan Medicine · USTexas Dermatology and Laser Specialists · US

Funding

VACCINIA PSA FOR ANDROGEN-MODULATED POST-SURGICAL RECURRENCE OF PROSTATE CANCERP50CA069568 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CHINNAIYAN, ARUL M · 1995 to 2013
$31.3M
Tissue/InformaticsP50CA186786 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Ganesh S Palapattu · 2014 to 2026
$27.6M
Multidiciplinary Integrative Genomic Approach to Distinguish Lethal from Indolent Prostate Cancer in Men of Europena and African AncestryU01CA196390 · NCI · JOHNS HOPKINS UNIVERSITY · PI DE MARZO, ANGELO MICHAEL, PIENTA, KENNETH J. · 2015 to 2020
$5.8M
Determining the clinical impact of gene expression testing in localized prostate cancerR01CA240991 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MORGAN, TODD M., SPRATT, DANIEL EIDELBERG · 2019 to 2024
$3.1M
NCI NIH HHS P50 CA069568NCI NIH HHS P50 CA186786NCI NIH HHS R01 CA240991NCI NIH HHS U01 CA196390
6 · The paper itself

Abstract

purposeThe heterogeneity of androgen receptor (AR)-activity (AR-A) is well-characterized in heavily treated metastatic castration-resistant prostate cancer (mCRPC). However, the diversity and clinical implications of AR-A in treatment-naïve primary prostate cancer is largely unknown. We sought to characterize AR-A in localized prostate cancer and understand its molecular and clinical implications. EXPERIMENTAL

designGenome-wide expression profiles from prostatectomy or biopsy samples from 19,470 patients were used, all with independent pathology review. This was comprised of prospective discovery (

resultsA low AR-active subclass was identified, which comprised 9%-11% of each cohort, and was characterized by increased immune signaling, neuroendocrine expression, and decreased DNA repair. These tumors were predominantly

conclusionsLeveraging large-scale transcriptomic data allowed the identification of an aggressive subtype of treatment-naïve primary prostate cancer that harbors molecular features more analogous to mCRPC. This suggests that a preexisting subgroup of patients may have tumors that are predisposed to fail multiple current standard-of-care therapies and warrant dedicated therapeutic investigation.

Indexed as

AgedAged, 80 and overBiomarkers, TumorCohort StudiesGenetic HeterogeneityHumansKaplan-Meier EstimateMaleMiddle AgedProstateProstatectomyProstate-Specific AntigenProstatic Neoplasms, Castration-ResistantReceptors, AndrogenTranscriptomeBiomarkers, TumorProstate-Specific AntigenReceptors, Androgen

Identifiers

PMID31515456
PMCPMC6858964
OpenAlexW2973096717

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.